BrainStorm Cell Therapeutics Inc. (BCLI) stock

BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 0/30

$0.77−0.01 (-1.17%)

Close on Oct 19, 2026Market cap $8.50MP/E –Yield –

BrainStorm Cell Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

BrainStorm Cell Therapeutics's EV/EBITDA was 16.6× on Jan 31, 2012.

Period	Period end	Value	Change (pts)
2012	Jan 31, 2012	16.6×	+1.6
2011	Dec 30, 2011	15.1×	–

See a number that looks wrong?